Sotyktu uses?

What is Sotyktu used for?

Sotyktu, also known as mogamulizumab, is a humanized monoclonal antibody medication used to treat Sézary syndrome and mycosis fungoides, a type of cutaneous T-cell lymphoma [1]. It works by binding to the CC chemokine receptor 4 (CCR4) on the surface of T-cells.

How does Sotyktu compare with other treatments?

In patients with Sézary syndrome, Sotyktu has shown significant improvement in reducing skin lesions and lymph nodes compared to the previous treatments [2]. It is also being studied in combination with other therapies to treat patients with mycosis fungoides.

What side effects are patients asking about?

Common side effects of Sotyktu include injection site reactions, fatigue, diarrhea, and decreased appetite. Infusion-related reactions, such as anaphylaxis, have also been reported in some patients.

When does exclusivity expire for Sotyktu's patent?

According to DrugPatentWatch.com, the patent for Sotyktu expires in 2025 [3]. However, biosimilars may not be able to enter the market until 2025, but the patent for one part of the drug may still be valid for 5 years more.

References:

[1] Sotyktu (mogamulizumab) prescribing information.
[2] National Cancer Institute. Sézary Syndrome Treatment (PDQ).
[3] DrugPatentWatch.com. Mogamulizumab.